NeoGenomics Inc (NEO)

[cashprofitsss]

NeoGenomics, Inc. Announces its Entry into the Flow Cytometry Testing Market

FT. MYERS, Fla.--(BUSINESS WIRE)--Feb. 9, 2005--NeoGenomics, Inc. (OTC BB: NGNM) announced today that it has received all regulatory approvals to offer flow cytometry testing services and has formally entered this market. Flow cytometry uses sophisticated laser-based equipment to analyze cell surface markers and is very effective at diagnosing certain types of cancer. Flow testing is also extremely complimentary to the Company's current cytogenetic and fluorescence in-situ hybridization (FISH) testing services and is generally performed on the same samples as these other tests. As a result the Company can now address approximately $1,200 - $1,400 of revenue per case of the oncology related tests performed for any one patient, whereas previously it only addressed approximately $700 per case of this potential revenue.

Bob Gasparini, the Company's President and Chief Scientific Officer, stated the following, "We are very excited about our entry into the flow market. By offering flow cytometry testing in addition to cytogenetics and FISH testing, we now offer a complete package of genetic-testing platforms to oncologists and pathologists. In addition to making it easier to market our services, we expect that the addition of flow cytometry testing will also allow us to increase our average revenue per case to nearly double what it is today."